PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. The company currently markets a portfolio of leading products in the acute-care hospital setting in the United States and Canada, and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies, based on its pioneering antibody humanization technology. Our product pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical development for hepatorenal syndrome, inflammatory and autoimmune diseases, cardiovascular disorders and cancer.